Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead's 2nd positive Phase III sets up early FDA submission for Quad

This article was originally published in Scrip

Executive Summary

Positive top-line results reported this week from a second Phase III study of Gilead Sciences' once-daily, fixed-dose, four-in-one HIV pill, known as Quad (emtricitabine, tenofovir disoproxil fumarate, evitegravir and cobicsta), has given the biotech giant the confidence it needed to move its timeline up for submitting a new drug application to the US FDA, which the company said will now occur before the end of this year rather than early next year.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts